Brief: SynAct Pharma Q3 Sales SEK 0
30/10/2024 06:30
Oct 30 (Reuters) - SynAct Pharma Q3 cash flow from operating activities SEK -24.076 million. * Q3 adjusted EPS SEK -0.5 * Q3 operating expenses SEK 24.309 million * Q3 net income SEK -20.489 million
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026